Dr. Scott Rocklage has been called a brilliant man by many. He attended the Massachusetts Institute of Technology, where he earned his Ph.D. in Chemistry. He also conducted some research in the laboratory of Nobel Prize winner Richard R. Schrock. Dr. Rocklage also has a B.S. in Chemistry, which he received while attended the University of California, Berkeley.
Currently, Dr. Scott Rocklage is a Managing Partner at 5AM Venture Management LLC. He joined the company in 2003, as a Venture Partner, and was named Managing Partner the following year. In May of 2016, he was also named Chief Executive Officer at EPIRUS Biopharmaceuticals, Inc. He didn’t serve as CEO for long, leaving the position that following July. He also served as Acting Chief Executive Officer but only for a month.
He’s also worked with Amersham Health. He served as Amersham’s CEO and President. He’s also served as Executive Chairman and Co-President at another company, Ilypsa, Inc. Dr. Rocklage’s career is filled with high-ranking positions that all led to his current position at 5AM Venture. The experience he gained at Cubist Pharmaceuticals, Inc would prove to be invaluable.
Like many professionals in his field, Dr. Rocklage has worked with several different institutions. It can be difficult to pinpoint exactly where it all started. For Dr. Rocklage, it all started at Nycomed Salutar, Inc. He served as Nycomed’s President and CEO from 1990 to 1994. Two years after joining Nycomed, he was given extra responsible as President and Chairman of Nycomed Interventional.
For years afterward, he worked with Salutar and Catalytica, serving in various research and development positions. All the experience earned over his career has made Dr. Rocklage one of the most sought after experts in the industry. He continues to serve as numerous high-ranking roles for many different companies.
Along with his amazing work history, Dr. Rocklage is also an inventor. Along with some fellow creators, Dr. Rocklage has over 30 U.S. patents. He also has over 100 publications that have been reviewed and approved by his peers.